fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Cefprozil

Form:

17 of 17 products shown

11 general benefit · 6 not a benefit

Auro-Cefprozil · DIN 02347261 · 125 mg/5 mL · Oral suspension-75mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347261 Manufacturer: Auro Pharma Inc.; listing date 2012-11-27 Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefprozil: Formulary list price $7.28 per unit (the source does not state the unit; exact figure $7.2750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02347261)

Source record
DIN 02347261: Auro-Cefprozil Raw flags: sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id AUR Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $7.2750; ministry $7.2750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347261 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83267
Interchangeable products
Cefzil · DIN 02163675 · not recorded Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347261
Shortage record checked October 6, 2026

Ran-Cefprozil · DIN 02329204 · 125 mg/5 mL · Oral suspension-75mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02329204 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Cefprozil: Formulary list price $7.28 per unit (the source does not state the unit; exact figure $7.2750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02329204)

Source record
DIN 02329204: Ran-Cefprozil Raw flags: sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id RAN Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $7.2750; ministry $7.2750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02329204 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81489
Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750 Cefzil · DIN 02163675 · not recorded
Shortage status: resolved shortage (ended August 21, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02329204
Shortage record checked October 6, 2026

Auro-Cefprozil · DIN 02347288 · 250 mg/5 mL · Oral suspension-75mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347288 Manufacturer: Auro Pharma Inc.; listing date 2012-11-27 Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefprozil: Formulary list price $14.54 per unit (the source does not state the unit; exact figure $14.5350). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02347288)

Source record
DIN 02347288: Auro-Cefprozil Raw flags: sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id AUR Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $14.5350; ministry $14.5350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347288 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83268
Interchangeable products
Cefzil · DIN 02163683 · not recorded Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347288
Shortage record checked October 6, 2026

Ran-Cefprozil · DIN 02293579 · 250 mg/5 mL · Oral suspension-75mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293579 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-09-04 Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Cefprozil: Formulary list price $14.54 per unit (the source does not state the unit; exact figure $14.5350). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293579)

Source record
DIN 02293579: Ran-Cefprozil Raw flags: sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id RAN Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $14.5350; ministry $14.5350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293579 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77893
Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350 Cefzil · DIN 02163683 · not recorded
Shortage status: resolved shortage (ended October 16, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293579
Shortage record checked October 6, 2026

Ran-Cefprozil · DIN 02293528 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293528 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06 Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Cefprozil: Formulary list price $1.74 per unit (the source does not state the unit; exact figure $1.7374). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293528)

Source record
DIN 02293528: Ran-Cefprozil Raw flags: sec3=Y Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id RAN Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $1.7374; ministry $1.7374 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293528 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77887
Interchangeable products
Cefzil · DIN 02163659 · not recorded
Shortage status: resolved shortage (ended December 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293528
Shortage record checked October 6, 2026

Auro-Cefprozil · DIN 02347253 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347253 Manufacturer: Auro Pharma Inc.; listing date 2012-04-24 Health Canada: Marketed since 2019-01-23 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefprozil: Formulary list price $2.00 per unit (the source does not state the unit; exact figure $2.0038). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02347253)

Source record
DIN 02347253: Auro-Cefprozil Raw flags: sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $2.0038; ministry $2.0038 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347253 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83266
Interchangeable products
Cefzil · DIN 02163667 · not recorded Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: resolved shortage (ended March 6, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347253
Shortage record checked October 6, 2026

Ran-Cefprozil · DIN 02293536 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293536 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06 Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Cefprozil: Formulary list price $2.00 per unit (the source does not state the unit; exact figure $2.0038). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293536)

Source record
DIN 02293536: Ran-Cefprozil Raw flags: sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id RAN Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $2.0038; ministry $2.0038 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293536 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77888
Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038 Cefzil · DIN 02163667 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293536
Shortage record checked October 6, 2026

Auro-Cefprozil · PIN 09858332 · 125 mg/5 mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Auro-Cefprozil · DIN 09858332 Manufacturer: Auro Pharma Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Auro-Cefprozil: Formulary list price $9.70 per unit (the source does not state the unit; exact figure $9.7000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858332)

Source record
DIN 09858332: Auro-Cefprozil Raw flags: sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id AUR Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $9.7000; ministry $9.7000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858332 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Cefzil · DIN 09857358 · not recorded Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858332
Shortage record checked October 6, 2026

Ran-Cefprozil · PIN 09857356 · 125 mg/5 mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Ran-Cefprozil · DIN 09857356 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Ran-Cefprozil: Formulary list price $9.70 per unit (the source does not state the unit; exact figure $9.7000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857356)

Source record
DIN 09857356: Ran-Cefprozil Raw flags: sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id RAN Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $9.7000; ministry $9.7000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857356 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000 Cefzil · DIN 09857358 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857356
Shortage record checked October 6, 2026

Auro-Cefprozil · PIN 09858333 · 250 mg/5 mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Auro-Cefprozil · DIN 09858333 Manufacturer: Auro Pharma Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Auro-Cefprozil: Formulary list price $19.38 per unit (the source does not state the unit; exact figure $19.3800). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858333)

Source record
DIN 09858333: Auro-Cefprozil Raw flags: sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id AUR Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.3800; ministry $19.3800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858333 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Cefzil · DIN 09857359 · not recorded Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858333
Shortage record checked October 6, 2026

Ran-Cefprozil · PIN 09857365 · 250 mg/5 mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Ran-Cefprozil · DIN 09857365 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Ran-Cefprozil: Formulary list price $19.38 per unit (the source does not state the unit; exact figure $19.3800). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857365)

Source record
DIN 09857365: Ran-Cefprozil Raw flags: sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id RAN Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.3800; ministry $19.3800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857365 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800 Cefzil · DIN 09857359 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857365
Shortage record checked October 6, 2026

Cefzil · PIN 09857358 · 125 mg/5 mL · Oral suspension-100mL Pk

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Cefzil · DIN 09857358 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857358)

Source record
DIN 09857358: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id BQU Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857358 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000 Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857358
Shortage record checked October 6, 2026

Cefzil · PIN 09857359 · 250 mg/5 mL · Oral suspension-100mL Pk

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Cefzil · DIN 09857359 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857359)

Source record
DIN 09857359: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id BQU Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857359 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800 Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857359
Shortage record checked October 6, 2026

Cefzil · DIN 02163675 · 125 mg/5 mL · Oral suspension-75mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163675 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2018-01-22 · brand CEFZIL POWDER FOR ORAL SUSPENSION-125MG/5ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 125 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163675)

Source record
DIN 02163675: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id BQU Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163675 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19227
Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750 Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: discontinued (December 29, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2018 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163683 · 250 mg/5 mL · Oral suspension-75mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.Discontinued September 14, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163683 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-09-14 · brand CEFZIL POWDER FOR ORAL SUSPENSION-250 MG/ 5 ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 250 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163683)

Source record
DIN 02163683: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id BQU Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163683 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19226
Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350 Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: discontinued (August 23, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163683
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 14, 2017 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163659 · 250 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.Discontinued August 2, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163659 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-08-02 · brand CEFZIL TABLETS - 250MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 250 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163659)

Source record
DIN 02163659: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id BQU Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163659 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19229
Interchangeable products
Ran-Cefprozil · DIN 02293528 · $1.7374
Shortage status: discontinued (June 30, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163659
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 2, 2017 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163667 · 500 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.Discontinued August 22, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163667 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-08-22 · brand CEFZIL TABLETS - 500MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cefzil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163667)

Source record
DIN 02163667: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id BQU Source form: Tab; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163667 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19228
Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038 Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: discontinued (July 31, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163667
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 22, 2017 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01D, J01DC): coverage varies; not interchangeable

  • Cefuroxime axetil (Ceftin): general benefit, not a benefit
  • Cefoxitin (Mefoxin): not a benefit
  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cephalexin (Ceporex): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE SPC-Cefprozil (cefprozil) is indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Upper Respiratory Tract Pharyngitis / tonsillitis caused by group A ß-hemolytic (GABHS) Streptococcus pyogenes. Substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present, although no case was reported during its evaluation in over 978 pediatric and 831 adult patients in controlled clinical trials. Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis. Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, (beta-lactamase positive and negative strains), and Moraxella (Branhamella) catarrhalis. Skin And Skin Structure Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Urinary Tract Uncomplicated urinary tract infections (including acute cystitis) caused by Escherichia coli, Pr SPC-Cefprozil – Product Monograph … https://pdf.hres.ca/dpd_pm/00080833.PDF PM date: JUN 18, 2025 Source product: SPC-CEFPROZIL; DIN 02293528; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Cefzil · DIN 02163675 Shortage status: discontinued (2017-12-29, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163675

Check this DIN again

Cefzil · DIN 02163683 Shortage status: discontinued (2017-08-23, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163683

Check this DIN again

Cefzil · DIN 02163659 Shortage status: discontinued (2017-06-30, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163659

Check this DIN again

Cefzil · DIN 02163667 Shortage status: discontinued (2017-07-31, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163667

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Cefzil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026